Antrim, United Kingdom

John Callan

This inventor holds 1 USPTO granted patent and 5 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Innovation Ulster Limited. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: John Callan: Innovator in Sonodynamic Therapy

Introduction

John Callan is a notable inventor based in Antrim, GB. He has made significant contributions to the field of medical technology, particularly in cancer treatment. His innovative approach focuses on enhancing therapeutic methods through the use of advanced materials.

Latest Patents

John Callan holds a patent for his invention related to sonodynamic therapy. The patent describes polymeric particles that consist of a matrix made from a biocompatible polymer and polyethylene imine. This matrix incorporates an anionic or hydrophobic sonosensitiser, along with optional immunomodulatory and imaging agents. These particles are designed for use in sonodynamic therapy, especially in conjunction with immunotherapy, targeting challenging cancers such as pancreatic cancer. He has 1 patent to his name.

Career Highlights

John Callan is associated with Innovation Ulster Limited, where he applies his expertise in developing innovative therapeutic solutions. His work is pivotal in advancing treatment options for patients with difficult-to-treat tumors.

Collaborations

He collaborates with talented individuals such as Anthony Mchale and Sian Farrell, contributing to a dynamic research environment focused on medical advancements.

Conclusion

John Callan's work in sonodynamic therapy exemplifies the intersection of innovation and healthcare. His contributions are vital in the ongoing fight against cancer, showcasing the potential of advanced therapeutic techniques.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…